|
Q3 FY2026
As of Aug 31, 2026
|
Q2 FY2026
As of May 31, 2026
|
Q1 FY2026
As of Feb 28, 2026
|
Q4 FY2025
As of Nov 30, 2025
|
|
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash | ||||
| Notes receivable | ||||
| Prepaid expenses | ||||
| Total current assets | ||||
| Long-term prepaid insurance | ||||
| Deferred offering costs | ||||
| Cash and investments held in Trust Account | ||||
| TOTAL ASSETS | ||||
| LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT | ||||
| Current liabilities | ||||
| Accounts payable and accrued expenses | ||||
| Accrued expenses | ||||
| Accrued expenses – related party | ||||
| Accrued offering costs | ||||
| Due to Sponsor | ||||
| Related Party | ||||
| Total due to Sponsor | ||||
| Promissory note – related party | ||||
| Total Current Liabilities | ||||
| Deferred legal fees | ||||
| Deferred underwriting fee | ||||
| Total Liabilities | ||||
| Ordinary shares subject to possible redemption, $0.0001 par value; 23,000,000 and no shares at redemption value of approximately $10.25 and $0 per share at August 31, 2026 and November 30, 2025, respectively | ||||
| Shareholders’ Deficit | ||||
| Ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 6,320,000 and 5,750,000 shares issued and outstanding (excluding 23,000,000 and no shares subject to possible redemption) at August 31, 2026 and November 30, 2025, respectively | ||||
| Additional paid-in capital | ||||
| Accumulated deficit | ||||
| Total Shareholders’ Deficit | ||||
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT |
Loading...